Content area
Full Text
[Image omitted] - (http://www.fiercebiotech.com/story/three-ipo-hopefuls-look-squeeze-out-144m-biotech-gets-bearish/2014-04-10) After a record-setting first quarter put billions in the pockets of drug developers, a second class of biotech upstarts is scrambling to cash out on Wall Street before an increasingly shaky market shuts the door on life sciences IPOs (http://www.fiercebiotech.com/tags/biotech-ipos). Dance Biopharm and Minerva Neurosciences are swinging for a combined $144 million, hoping the industry's rough couple of weeks won't sully their planned debuts.
First up is Dance, a Brisbane, CA, outfit seeking up to $75 million to get its inhaled insulin to market. Like the headline-grabbing Afrezza from MannKind ($MNKD), Dance's product is a drug-device combo that promises to free diabetics from inconvenient injections, but, in contrast to the former's dry-powder formulation, Dance...